Gilteritinib monotherapy for R/R FLT3-mutated AML
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-GILTERITINIB |
|---|
| ID | REG-GILTERITINIB-AML |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ADMIRAL-PERL-2019 SRC-ELN-AML-2022 SRC-NCCN-AML-2025 |
Notes
Standard 2L+ for R/R FLT3-mutated AML per ADMIRAL. Bridge to alloHCT for fit candidates achieving CR/CRh — gilteritinib alone is not curative. Continue gilteritinib post-HCT as maintenance (off-label, supported by emerging data MORPHO trial). STUB — pending Co-Lead sign-off.
Used By
Indication
IND-AML-2L-GILTERITINIB-FLT3- IND-AML-2L-GILTERITINIB-FLT3